The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial)
Joy L, Jolien R, Marithé C, Stijn E, Laura S, Hilde L, Sandra B, Wendy N, Ruth H, Liesbeth R, Sylvana S, Sylvia H, Jeroen M
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 21 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Universiteit Hasselt
- Organización sin fines de lucro
- Kom op tegen Kanker
- Organización sin fines de lucro
- Stand Up To Cancer
- Organización sin fines de lucro
- Limburgs Kankerfonds
- Organización sin fines de lucro
- Limburgse Kankersamenwerking
- Universidad u hospital
- Limburg Clinical Research Center
Según 6 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2022-03-21 · Support Care Cancer · vol. 30 · número 6 · págs. 5509–5517
- Editorial
- Springer Science+Business Media
- Citado
- 26 citas · más que el 90% de estudios similares · 2.1× el promedio de su campo
- Referencias
- 46 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Cancer Treatment and Pharmacology · Laser Applications in Dentistry and Medicine · Chemotherapy-related skin toxicity
- Palabras clave
- low-level laser therapy, chemotherapy-induced peripheral neuropathy, breast cancer, neuropathy prevention, quality of life, pain, walking distance
- MeSH
- humans, breast neoplasms, pain, peripheral nervous system diseases, taxoids, antineoplastic agents, prospective studies, pilot projects, quality of life, female, low-level light therapy
13 autores
- Joy Lodewijckx🇧🇪 · autor de correspondenciaHasselt University
- Jolien Robijns🇧🇪Hasselt University
- Marithé Claes🇧🇪Hasselt University
- Evens Stijn🇧🇪Hasselt University
- Swinnen Laura🇧🇪Hasselt University
- Lenders Hilde🇧🇪Jessa Hospital
- Bortels Sandra🇧🇪Jessa Hospital
- Nassen Wendy🇧🇪Jessa Hospital
- Hilkens Ruth🇧🇪Jessa Hospital
- Raymakers Liesbeth🇧🇪Jessa Hospital
- Snoekx Sylvana🇧🇪Jessa Hospital
- Sylvia Hermans🇧🇪Jessa Hospital
- Jeroen Mebis🇧🇪Jessa Hospital; Hasselt University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
The purpose of this study was to investigate the effectiveness of photobiomodulation (PBM) therapy for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients.
Methods
A prospective, randomized placebo-controlled pilot trial (NEUROLASER) was set up with 32 breast cancer patients who underwent chemotherapy (ClinicalTrials.gov; NCT03391271). Patients were randomized to receive PBM (n = 16) or placebo treatments (n = 16) (2 × /week) during their chemotherapy. The modified Total Neuropathy Score (mTNS), six-minute walk test (6MWT), Numeric pain Rating Scale (NRS), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Taxane (FACT/GOG-Taxane) were used to evaluate the severity of CIPN and the patients' quality of life (QoL). Outcome measures were collected at the first chemotherapy session, 6 weeks after initiation of chemotherapy, at the final chemotherapy session, and 3 weeks after the end of chemotherapy (follow-up).
Results
The mTNS score increased significantly over time in both the control and the PBM group. A significantly higher score for FACT/GOG-Taxane was observed in the PBM group during chemotherapy compared to the control group. Questions of the FACT/GOG-Taxane related to sensory peripheral neuropathy symptoms showed a significant increase in severeness over time in the control group, whereas they remained constant in the PBM group. At follow-up, a (borderline) significant difference was observed between both groups for the 6MWT and patients' pain level, in benefit of the PBM group.
Conclusions
This NEUROLASER trial shows promising results concerning the prevention of CIPN with PBM in breast cancer patients. Furthermore, a better QoL was observed when treated with PBM.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.